IRD Q4 2023 Earnings — Opus Genetics, Inc. Revenue & Financial Results | Market Cap Arena

IRDOpus Genetics, Inc.

$349M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-95.8% YoY

Gross Profit

-$3M-177.8% margin

Operating Income

-$5M-321.1% margin

Net Income

-$5M-283.6% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

-85.8%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$5M

Stock-Based Comp.

$711,000

Balance Sheet

Total Assets

$54M

Total Liabilities

$4M

Stockholders' Equity

$50M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$40M	-95.8%
Gross Profit	-$3M	$40M	-107.5%
Operating Income	-$5M	$34M	-115.9%
Net Income	-$5M	$34M	-114.1%